-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Crosses Above Fifty Day Moving Average of $3.72
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Crosses Above Fifty Day Moving Average of $3.72
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.72 and traded as high as $3.93. ZIVO Bioscience shares last traded at $3.80, with a volume of 5,352 shares trading hands.
ZIVO Bioscience Stock Down 0.8 %
The company's 50 day moving average price is $3.72 and its 200 day moving average price is $3.55.
Get ZIVO Bioscience alerts:Institutional Inflows and Outflows
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. boosted its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent quarter. Institutional investors own 5.54% of the company's stock.
ZIVO Bioscience Company Profile
(Get Rating)ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Further Reading
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.72 and traded as high as $3.93. ZIVO Bioscience shares last traded at $3.80, with a volume of 5,352 shares trading hands.
Zivo Bioscience,Inc.(场外交易市场代码:Zivo-GET评级)在周三的交易中超过了50日移动均线。该股的50日移动均线切入位为3.72美元,最高交易价格为3.93美元。Zivo Bioscience的股票最新报3.80美元,成交量为5352股。
ZIVO Bioscience Stock Down 0.8 %
Zivo Bioscience股价下跌0.8%
The company's 50 day moving average price is $3.72 and its 200 day moving average price is $3.55.
该公司的50日移动均线价格为3.72美元,其200日移动均线价格为3.55美元。
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. boosted its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent quarter. Institutional investors own 5.54% of the company's stock.
一家机构投资者最近提高了对Zivo Bioscience股票的头寸。先锋集团(Vanguard Group Inc.)在最近一次向美国证券交易委员会(Securities&Exchange Commission)披露的信息中称,该公司第一季度将其在Zivo Bioscience,Inc.(场外交易市场代码:Zivo-GET)的头寸提高了19.6%。该机构投资者在本季度额外购买了15,147股后,持有这家生物技术公司的92,468股股票。截至最近一个季度末,先锋集团持有Zivo Bioscience 0.98%的股份,价值35.9万美元。机构投资者持有该公司5.54%的股份。
ZIVO Bioscience Company Profile
Zivo生物科学公司简介
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience,Inc.是一家研发公司,致力于向动物、人类、膳食补充剂和医用食品制造商许可和销售从其专有藻类培养物中提取的天然生物活性成分。它在生物技术和农业技术部门开展业务,拥有知识产权组合,包括专有藻类和细菌菌株、生物活性分子和复合体、生产技术、栽培技术,以及应用于人类和动物健康的专利或正在申请专利的发明。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
- 免费获取StockNews.com关于Zivo生物科学的研究报告(Zivo)
- 哪些半导体类股准备好迎接价格大幅波动?
- 尽管面临更广泛的经济挑战,矿商的收益仍在上涨
- 安捷伦科技对Illumina证明了自己的价值
- Lowe‘s在第二季度零售报告中脱颖而出
- 塔吉特的业绩上限零售类股的上行潜力
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zivo生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zivo Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧